Little Known Facts About BMS-199264 hydrochloride.
All enrolled patients who gained no less than 1 dose of zosuquidar or placebo for the duration of induction had been monitored for that prevalence of adverse gatherings (439 patients, 219 on zosuquidar and 210 on placebo). The most common adverse functions were being linked to the duration of prolonged and important myelosuppression as is expected